Aftab Waqas, Varadarajan Padmini, Rasool Shuja, Pai Ramdas G
Division of Cardiology, Loma Linda University Medical Center, Loma Linda, California.
Int J Angiol. 2014 Jun;23(2):131-8. doi: 10.1055/s-0034-1372248.
Renal transplantation is the treatment of choice in patients with end-stage renal disease. Major adverse cardiac events (MACE) are common after renal transplant, especially in the perioperative period, leading to excess morbidity and mortality. The predictors and long-term prognostic implications of MACE are poorly understood. We analyzed predictors and implications of MACE in a cohort of 321 consecutive adult patients, who received renal allograft transplantation between 1995 and 2003 at our institution. The characteristics of 321 patients were: age at transplant 44 ± 13 years, 60% male, 36% diabetes mellitus (DM), left ventricular ejection fraction (LVEF) 60 ± 16%. MACE occurred in 21 patients with cumulative rate of 6.5% over 3 years after renal transplant, 57% occurring within 30 days, 67% within 90 days, and 86% within 180 days. MACE was not predicted by any clinical or pharmacological variables including age, gender, hypertension, DM, prior myocardial infarction, smoking, duration of dialysis, LVEF, or therapy with β-blockers (BB), angiotensin converting enzyme inhibitors, or calcium channel blockers. However, a clinical decision to perform a stress test or a coronary angiogram was predictive of higher MACE rate. MACE, irrespective of type, was independently associated with higher mortality over a period up to 15 years and this seemed to be blunted by BB therapy. MACE rate after renal transplantation decreases over time, most occurring in the first 90 days and is not predicted by any of the traditional risk factors or drug therapies. It is associated with higher long-term mortality.
肾移植是终末期肾病患者的首选治疗方法。肾移植后主要不良心脏事件(MACE)很常见,尤其是在围手术期,会导致发病率和死亡率增加。MACE的预测因素和长期预后影响尚不清楚。我们分析了1995年至2003年间在我们机构接受同种异体肾移植的321例连续成年患者队列中MACE的预测因素和影响。321例患者的特征为:移植时年龄44±13岁,男性占60%,糖尿病(DM)占36%,左心室射血分数(LVEF)60±16%。21例患者发生MACE,肾移植后3年累积发生率为6.5%,57%发生在30天内,67%发生在90天内,86%发生在180天内。包括年龄、性别、高血压、DM、既往心肌梗死、吸烟、透析时间、LVEF或β受体阻滞剂(BB)、血管紧张素转换酶抑制剂或钙通道阻滞剂治疗在内的任何临床或药理学变量均不能预测MACE。然而,进行负荷试验或冠状动脉造影的临床决策可预测较高的MACE发生率。无论类型如何,MACE在长达15年的时间内与较高的死亡率独立相关,而BB治疗似乎可减轻这种情况。肾移植后的MACE发生率随时间下降,大多数发生在最初90天内,且不能由任何传统危险因素或药物治疗预测。它与较高的长期死亡率相关。